Biopharma Analysts Chen & Leung, Biotech Analysts Kim & Brayer, along with Dr. Ruoss, Professor of Medicine at Stanford University, discuss new and emerging treatments for Nontuberculous Mycobacteria (NTM) (relevant companies INSM, SPRO, ANTX, MNKD) on an Analyst/Industry conference call to be held on March 5 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSM:
- Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
- Insmed price target raised to $54 from $52 at Guggenheim
- Insmed initiated with a Buy at UBS
- 3 Best Stocks to Buy Now, 2/26/2024, According to Top Analysts
- Insmed price target raised to $40 from $37 at BofA
Questions or Comments about the article? Write to editor@tipranks.com